Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor

Molecular Therapy

Volumn 21, Issue 3, 2013, Pages 638-647

  Deniger, Drew C ^a,b   Switzer, Kirsten ^a   Mi, Tiejuan ^a   Maiti, Sourindra ^a   Hurton, Lenka ^a,b   Singh, Harjeet ^a   Huls, Helen ^a   Olivares, Simon ^a   Lee, Dean A ^a,b   Champlin, Richard E ^a   Cooper, Laurence JN ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; MESSENGER RNA; T LYMPHOCYTE RECEPTOR;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CANCER CELL CULTURE; CELL SPECIFICITY; CONTROLLED STUDY; ELECTROPORATION; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LEUKEMIA; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN DETERMINATION; T LYMPHOCYTE SUBPOPULATION; TRANSPOSON;

MUS;

EID: 84875226632     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.267     Document Type: Article

References (51)

1. Singh, H, Manuri, PR, Olivares, S, Dara, N, Dawson, MJ, Huls, H et al. (2008). Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res 68: 2961-2971.
2. Kowolik, CM, Topp, MS, Gonzalez, S, Pfeiffer, T, Olivares, S, Gonzalez, N et al. (2006). CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 66: 10995-11004.
3. Jena, B, Dotti, G and Cooper, LJ (2010). Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 116: 1035-1044.
4. Cooper, LJ, Topp, MS, Serrano, LM, Gonzalez, S, Chang, WC, Naranjo, A et al. (2003). T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 101: 1637-1644.
5. Singh, H, Figliola, MJ, Dawson, MJ, Huls, H, Olivares, S, Switzer, K et al. (2011). Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res 71: 3516-3527.
6. Brentjens, RJ, Rivière, I, Park, JH, Davila, ML, Wang, X, Stefanski, J et al. (2011). Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118: 4817-4828.
7. Porter, DL, Levine, BL, Kalos, M, Bagg, A and June, CH (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365: 725-733.
8. Kalos, M, Levine, BL, Porter, DL, Katz, S, Grupp, SA, Bagg, A et al. (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3: 95ra73.
9. Kochenderfer, JN, Wilson, WH, Janik, JE, Dudley, ME, Stetler-Stevenson, M, Feldman, SA et al. (2010). Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116: 4099-4102.
10. Castella, B, Vitale, C, Coscia, M and Massaia, M (2011). Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside. Cell Mol Life Sci 68: 2419-2432.
11. Brandes, M, Willimann, K, Bioley, G, Lévy, N, Eberl, M, Luo, M et al. (2009). Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses. Proc Natl Acad Sci USA 106: 2307-2312.
12. Gomes, AQ, Martins, DS and Silva-Santos, B (2010). Targeting T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application. Cancer Res 70: 10024-10027.
13. Scotet, E, Martinez, LO, Grant, E, Barbaras, R, Jenö, P, Guiraud, M et al. (2005). Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity 22: 71-80.
14. Hayday, AC (2000). [gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 18: 975-1026.
15. Kondo, M, Sakuta, K, Noguchi, A, Ariyoshi, N, Sato, K, Sato, S et al. (2008). Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy 10: 842-856.
16. Chiplunkar, S, Dhar, S, Wesch, D and Kabelitz, D (2009). gammadelta T cells in cancer immunotherapy: current status and future prospects. Immunotherapy 1: 663-678.
17. Lamb, LS Jr, Henslee-Downey, PJ, Parrish, RS, Godder, K, Thompson, J, Lee, C et al. (1996). Increased frequency of TCR gamma delta + T cells in disease-free survivors following T cell-depleted, partially mismatched, related donor bone marrow transplantation for leukemia. J Hematother 5: 503-509.
18. Lamb, LS Jr, Gee, AP, Hazlett, LJ, Musk, P, Parrish, RS, O'Hanlon, TP et al. (1999). Influence of T cell depletion method on circulating gammadelta T cell reconstitution and potential role in the graft-versus-leukemia effect. Cytotherapy 1: 7-19.
19. Lamb, LS Jr, Musk, P, Ye, Z, van Rhee, F, Geier, SS, Tong, JJ et al. (2001). Human gammadelta(+) T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response. Bone Marrow Transplant 27: 601-606.
20. Godder, KT, Henslee-Downey, PJ, Mehta, J, Park, BS, Chiang, KY, Abhyankar, S et al. (2007). Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant 39: 751-757.
21. Numbenjapon, T, Serrano, LM, Singh, H, Kowolik, CM, Olivares, S, Gonzalez, N et al. (2006). Characterization of an artificial antigen-presenting cell to propagate cytolytic CD19-specific T cells. Leukemia 20: 1889-1892.
22. Zhang, M, Maiti, S, Bernatchez, C, Huls, H, Rabinovich, B, Champlin, RE et al. (2012). A new approach to simultaneously quantify both Tcr α- and β-chain diversity after adoptive immunotherapy. Clin Cancer Res: Off J Am Assoc Cancer Res 18(17): 4733-4742.
23. Rischer, M, Pscherer, S, Duwe, S, Vormoor, J, Jürgens, H and Rossig, C (2004). Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity. Br J Haematol 126: 583-592.
24. Hanrahan, CF, Kimpton, WG, Howard, CJ, Parsons, KR, Brandon, MR, Andrews, AE et al. (1997). Cellular requirements for the activation and proliferation of ruminant gammadelta T cells. J Immunol 159: 4287-4294.
25. Nagamine, I, Yamaguchi, Y, Ohara, M, Ikeda, T and Okada, M (2009). Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer. Hiroshima J Med Sci 58: 37-44.
26. García, VE, Jullien, D, Song, M, Uyemura, K, Shuai, K, Morita, CT et al. (1998). IL-15 enhances the response of human gamma delta T cells to nonpeptide [correction of nonpetide] microbial antigens. J Immunol 160: 4322-4329.
27. Do, JS and Min, B (2009). IL-15 produced and trans-presented by DCs underlies homeostatic competition between CD8 and {gamma}{delta} T cells in vivo. Blood 113: 6361-6371.
28. Thedrez, A, Harly, C, Morice, A, Salot, S, Bonneville, M and Scotet, E (2009). IL-21- mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy. J Immunol 182: 3423-3431.
29. O'Connor, CM, Sheppard, S, Hartline, CA, Huls, H, Johnson, M, Palla, SL et al. (2012). Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy. Sci Rep 2: 249.
30. Kelly-Rogers, J, Madrigal-Estebas, L, O'Connor, T and Doherty, DG (2006). Activationinduced expression of CD56 by T cells is associated with a reprogramming of cytolytic activity and cytokine secretion profile in vitro. Hum Immunol 67: 863-873.
31. Smetak, M, Kimmel, B, Birkmann, J, Schaefer-Eckart, K, Einsele, H, Wilhelm, M et al. (2008). Clinical-scale single-step CD4(+) and CD8(+) cell depletion for donor innate lymphocyte infusion (DILI). Bone Marrow Transplant 41: 643-650.
32. Klebanoff, CA, Gattinoni, L and Restifo, NP (2006). CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev 211: 214-224.
33. Di Mitri, D, Azevedo, RI, Henson, SM, Libri, V, Riddell, NE, Macaulay, R et al. (2011). Reversible senescence in human CD4+CD45RA+CD27- memory T cells. J Immunol 187: 2093-2100.
34. Kulkarni, MM (2011). Digital multiplexed gene expression analysis using the NanoString nCounter system. Curr Protoc Mol Biol Chapter 25: Unit25B.10.
35. Kang, N, Zhou, J, Zhang, T, Wang, L, Lu, F, Cui, Y et al. (2009). Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibodyexpanded human gammadelta T-cells in peripheral blood. Cancer Biol Ther 8: 1540-1549.
36. Dokouhaki, P, Han, M, Joe, B, Li, M, Johnston, MR, Tsao, MS et al. (2010). Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: A new approach. Cancer Lett 297: 126-136.
37. Lopez, RD, Xu, S, Guo, B, Negrin, RS and Waller, EK (2000). CD2-mediated IL-12-dependent signals render human gamma delta-T cells resistant to mitogeninduced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the development of adoptive immunotherapy strategies. Blood 96: 3827-3837.
38. Brandes, M, Willimann, K and Moser, B (2005). Professional antigen-presentation function by human gammadelta T Cells. Science 309: 264-268.
39. Newton, DJ, Andrew, EM, Dalton, JE, Mears, R and Carding, SR (2006). Identification of novel gammadelta T-cell subsets following bacterial infection in the absence of Vgamma1+ T cells: homeostatic control of gammadelta T-cell responses to pathogen infection by Vgamma1+ T cells. Infect Immun 74: 1097-1105.
40. Olofsson, K, Hellström, S and Hammarström, ML (1998). The surface epithelium of recurrent infected palatine tonsils is rich in gammadelta T cells. Clin Exp Immunol 111: 36-47.
41. Knight, A, Madrigal, AJ, Grace, S, Sivakumaran, J, Kottaridis, P, Mackinnon, S et al. (2010). The role of Vδ2-negative γδ T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation. Blood 116: 2164-2172.
42. Stresing, V, Daubiné, F, Benzaid, I, Mönkkönen, H and Clézardin, P (2007). Bisphosphonates in cancer therapy. Cancer Lett 257: 16-35.
43. Angelini, DF, Borsellino, G, Poupot, M, Diamantini, A, Poupot, R, Bernardi, G et al. (2004). FcgammaRIII discriminates between 2 subsets of Vgamma9Vdelta2 effector cells with different responses and activation pathways. Blood 104: 1801-1807.
44. Haas, JD, Nistala, K, Petermann, F, Saran, N, Chennupati, V, Schmitz, S et al. (2011). Expression of miRNAs miR-133b and miR-206 in the Il17a/f locus is co-regulated with IL-17 production in and T cells. PLoS ONE 6: e20171.
45. Kryczek, I, Wei, S, Zou, L, Altuwaijri, S, Szeliga, W, Kolls, J et al. (2007). Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 178: 6730-6733.
46. Lai, D, Wang, F, Chen, Y, Wang, C, Liu, S, Lu, B et al. (2012). Human ovarian cancer stem-like cells can be efficiently killed by γδ T lymphocytes. Cancer Immunol Immunother 61: 979-989.
47. Middleton, GW, Annels, NE and Pandha, HS (2012). Are we ready to start studies of Th17 cell manipulation as a therapy for cancer? Cancer Immunol Immunother 61: 1-7.
48. Cua, DJ and Tato, CM (2010). Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 10: 479-489.
49. Haas, JD, González, FH, Schmitz, S, Chennupati, V, Föhse, L, Kremmer, E et al. (2009). CCR6 and NK1.1 distinguish between IL-17A and IFN-gamma-producing gammadelta effector T cells. Eur J Immunol 39: 3488-3497.
50. Paulos, CM, Carpenito, C, Plesa, G, Suhoski, MM, Varela-Rohena, A, Golovina, TN et al. (2010). The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells. Sci Transl Med 2: 55ra78.
51. Manuri, PV, Wilson, MH, Maiti, SN, Mi, T, Singh, H, Olivares, S et al. (2010). piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther 21: 427-437.